

Table S1. Clinicopathological characteristics.

Variable	Cases [n, (% or IQR)]
Median age, years (IQR)	65 (61-69)
Overweight, n (%)	
Absence	430 (68.8)
Presence	195 (31.2)
Median PSA at diagnosis, ng/ml (IQR)	7.1 (5.3-10.0)
Median prostate volume at diagnosis, ml (IQR)	26 (20-34)
Clinical stage, n (%)	
cT1	192 (30.7)
cT2	394 (63.0)
cT3/4	39 (6.2)
Biopsy gleason score, n (%)	
<7	160 (25.6)
7	323 (51.7)
>7	142 (22.7)
Nerve sparing, n (%)	
None	384 (61.4)
Ipsilateral	126 (20.2)
Bilateral	115 (18.4)
Lympho-node dissection, n (%)	
No procedure	401 (64.2)
Underwent procedure	224 (35.8)
Pathological stage, n (%)	
pT0	8 (1.3)
pT2	438 (70.1)
pT3a	145 (23.2)
pT3b	34 (5.4)
Surgical margin, n (%)	
Negative	478 (77.5)
Positive	139 (22.5)
Undetermined	8
Pathological Gleason score, n (%)	
<7	53 (9.2)
7	430 (74.9)
>7	91 (15.9)
Undetermined	51
Changes in Gleason score, n (%)	
Downgrade	72 (11.5)
No change	353 (56.5)
Upgrade	149 (23.8)
Undetermined	51
Lympho-node status, n (%)	
Negative	190 (84.8)
Positive	34 (15.2)

IQR, interquartile range; PSA, prostate-specific antigen.

Table S2. Perioperative outcomes in robot-assisted radical prostatectomy.

Variable	Cases, n (IQR or %)
Median total operation time, min (IQR)	235 (199-289)
Median console-operation time, min (IQR)	177 (144-234)
Median estimated blood loss, ml (IQR)	200 (100-350)
Median catheterization duration, day (IQR)	6 (5-7)
Perioperative comorbidity, n (%)	
Any grade/grade ≥3	100 (16.0)/ 13 (2.1)

IQR, interquartile range.